Leticia M. Lazinski, Morane Beaumet, Frédérique Loiseau, Cyril Goudet, Martial Boggio-Pasqua, Guy Royal, Romain Haudecoeur
{"title":"Bistable and Water-Operable Hemiindigo Photoswitches Allow Optical Control of Acetylcholinesterase Activity with Visible Light","authors":"Leticia M. Lazinski, Morane Beaumet, Frédérique Loiseau, Cyril Goudet, Martial Boggio-Pasqua, Guy Royal, Romain Haudecoeur","doi":"10.1002/ceur.202500221","DOIUrl":null,"url":null,"abstract":"<p>While photopharmacology enables precise spatiotemporal control over drug activity, its widespread reliance on UV-responsive molecules often hinders preclinical and clinical advancements. Thus, alternative scaffolds can offer promising advantages over the commonly used azobenzene family. In this study, we introduce the first hemiindigo-based photopharmacological agents, which are capable of isomer-dependent human acetylcholinesterase inhibition in the nanomolar range. These hemiindigo photoswitches exhibit highly favorable properties: They are fully functional in aqueous medium with good photoisomerization quantum yields, respond exclusively to blue-to-orange visible light (415–590 nm), and maintain high stability in their metastable form, even in physiological buffers. Notably, indoxyl <i>N</i>-methylation emerged as a key structural feature for optimizing photophysical properties, as demonstrated through crystallography and a theoretical model describing the photochemical pathways governing photoisomerization. Overall, this study paves the way for broader exploration and future applications of the largely overlooked hemiindigo scaffold in photopharmacology.</p>","PeriodicalId":100234,"journal":{"name":"ChemistryEurope","volume":"3 5","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://chemistry-europe.onlinelibrary.wiley.com/doi/epdf/10.1002/ceur.202500221","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ChemistryEurope","FirstCategoryId":"1085","ListUrlMain":"https://chemistry-europe.onlinelibrary.wiley.com/doi/10.1002/ceur.202500221","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
While photopharmacology enables precise spatiotemporal control over drug activity, its widespread reliance on UV-responsive molecules often hinders preclinical and clinical advancements. Thus, alternative scaffolds can offer promising advantages over the commonly used azobenzene family. In this study, we introduce the first hemiindigo-based photopharmacological agents, which are capable of isomer-dependent human acetylcholinesterase inhibition in the nanomolar range. These hemiindigo photoswitches exhibit highly favorable properties: They are fully functional in aqueous medium with good photoisomerization quantum yields, respond exclusively to blue-to-orange visible light (415–590 nm), and maintain high stability in their metastable form, even in physiological buffers. Notably, indoxyl N-methylation emerged as a key structural feature for optimizing photophysical properties, as demonstrated through crystallography and a theoretical model describing the photochemical pathways governing photoisomerization. Overall, this study paves the way for broader exploration and future applications of the largely overlooked hemiindigo scaffold in photopharmacology.